The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite delivery contract to Glenmark Pharmaceuticals Inc., USA to supply Zolmitriptan orally disintegrating and tablet formulations. The contract has a potential value of $1,734,148.80 over a one-year base period and four one-year option periods extending to January 2023.
The original solicitation sought unrestricted offers for an uninterrupted supply of Zolmitriptan to support the pharmaceutical needs of the VA, DoD, Bureau of Prisons, and Indian Health Service. The solicitation specified annual estimates of 20,380 blister packs of 2.5mg orally disintegrating tablets, 79,667 packs of 5mg orally disintegrating tablets, 34,715 packs of 2.5mg tablets, and 124,824 packs of 5mg tablets. The contract aims to leverage the VA's and DoD's Pharmaceutical Prime Vendor programs to efficiently distribute the migraine treatment medications to served agencies and patients.
Generated 1/5/24, 2:03 AM